Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid - Lipton, A (Cancer, 2008)
[Subset analyses of this larger study have previously been published by: Lipton A et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007; 12: 1035-1043. Hirsh V, Major PP, Lipton A et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008; 3: 228-236.].